FUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FUL is not a strong buy right now for a beginner long-term investor with $50,000-$100,000, given the mixed technical setup and the lack of a clear proprietary buy signal. The company’s fundamentals and analyst sentiment are improving, but the current price is sitting near support with bearish momentum still present, so I would not call this an immediate buy. If forced to act now, hold rather than buy.
FUL is trading at 58.06, just above S1 support at 57.974 and below the pivot at 61.283, which suggests the stock is still in a weak short-term posture. MACD histogram is -0.789 and negatively expanding, pointing to ongoing bearish momentum. RSI_6 at 31.496 is near oversold but not yet a decisive reversal signal. Moving averages are converging, which can precede a trend change, but current evidence does not confirm one. The stock trend data also implies near-term weakness, with projected performance of +0.51% next day, -2.29% next week, and -2.59% next month.
Q2 2026 results were strong: adjusted EBITDA rose 9% year over year to $181 million and revenue reached $950.3 million, both ahead of expectations. Operating cash flow hit a record $121 million, and net debt to adjusted EBITDA improved to 3.1x. Analysts have been raising targets and generally remain positive, and the company’s push into medical adhesives via the Advanced Medical Solutions offer could support longer-term growth.
The stock is facing near-term technical weakness, with bearish MACD momentum and price below the pivot. H.B. Fuller also expects a 4%-6% decline in volume in H2 2026, which could pressure near-term growth. The Advanced Medical Solutions acquisition introduces some risk/overhang, and options positioning is slightly bearish. Similar candlestick pattern analysis also points to weakness over the next week and month.
Latest quarter: Q2 2026. Revenue increased to $950.3 million, ahead of consensus, and adjusted EBITDA rose 9% year over year to $181 million. Cash generation was strong, with record operating cash flow of $121 million. Balance sheet leverage improved to 3.1x net debt/adjusted EBITDA. The quarter shows improving profitability and cash flow, though management still expects lower volumes in the second half of 2026.
Analyst sentiment is constructive and improving. Deutsche Bank raised its target to $72 and kept Buy, Citi raised its target to $75 and kept Buy, JPMorgan upgraded to Overweight with a $67 target, and UBS raised its target to $71 while remaining Neutral. Seaport lowered its target to $80 from $84 but still kept Buy due to acquisition-related risk. Overall Wall Street pros: improving EBITDA, better cash flow, price/mix strength, and leverage improvement. Cons: volume declines, acquisition execution risk, and some valuation/overhang concerns. No recent politician or congress trading activity was reported.
